Posted by Michael Wonder on 05 Oct 2022
Immutep receives FDA fast track designation for LAG-3 therapeutic eftilagimod alfa for first-line non-small-cell lung cancer
4 October 2022 - Based on the encouraging Phase 2 clinical data for PD-L1 all-comers presented at ASCO 2022.
Immutep today announced the US FDA has granted fast track designation to eftilagimod alfa in combination with pembrolizumab for the treatment of first-line non-small-cell lung cancer.
